Vascular calcification (VC) is a strong prognostic marker of cardiovascular disease mortality, and VC can be classified into intima-based VC and media-based VC. 1 Chronic kidney disease (CKD), diabetes mellitus and ageing always complicate medial VC. In addition to kidney damage, vascular stiffness by CKD-associated VC also leads to escalated cardiovascular mortality. 2 Though passive deposition of hydroxyapatites is considered the main pathological process of VC, recent studies have reported VC to be a complex process with involvement of different molecular pathways, which includes active transformation of vascular smooth muscle cell (VSMC) into osteoblast-like cells. 3
as deciding the fate of stem cells. 4 The degradation of cytoplasmic β-catenin is inhibited when the pathway is activated, and subsequently, accumulated β-catenin enters the nucleus where it regulates downstream gene expression. 5, 6 Increasing evidence has indicated that the activation of the Wnt/β-catenin pathway plays a key role in VC. [7] [8] [9] For example, the Wnt/β-catenin pathway promoted VSMC osteogenic transdifferentiation by modulating RUNX2 expression. 7 Furthermore, inhibition of the Wnt/β-catenin pathway was demonstrated to ameliorate VC. 10 Peroxisome proliferator-activated receptor gamma (PPAR-γ) belongs to the nuclear hormone receptor superfamily. PPAR-γ is expressed in various cell types and regulates certain cellular metabolism and differentiation processes. 11 The mutual antagonism between PPAR-γ and the Wnt/β-catenin pathway has been demonstrated to regulate the differentiation of mesenchymal stem cells (MSCs) into adipocytes and osteoblasts. 12 In addition, pioglitazone, a PPAR-γ agonist, has been suggested to inhibit the canonical Wnt pathway, which attenuates VC. 13 Ginsenosides are major components of the traditional herbal medicine ginseng, and ginsenosides can be classified into panaxadiols (PPD) and panaxatriols (PPT) by chemical structure. Rb1, the most abundant constituent of panaxadiol, has recently been reported to exert protective properties in vascular diseases and kidney diseases. [14] [15] [16] [17] A clinical study indicated that Rb1 alleviated creatine and inflammatory cytokine levels in CKD patients. 18 Furthermore, it has been reported that Rb1 reduced type I collagen expression through PPAR-δ, which is considered an osteogenic profile marker of VSMC. 19, 20 However, the role of ginsenoside Rb1 in CKD-associated VC has not yet been studied.
In view of the demonstration that Rb1 acts as a PPAR-γ agonist in human umbilical vein endothelial cells (HUVECs) by our previous study, 21 we hypothesized that ginsenoside Rb1 may protect VC through the PPAR-γ/β-catenin axis. To test our hypothesis, we established a CKD rat model and a VSMC calcification model to mimic clinical CKD-associated VC in vivo and in vitro. Antibodies against calponin 1 (#17819), runt-related transcription factor 2 (RUNX2; #12556), β-catenin (#8480), phospho-β-catenin (Ser675) (#9567), glycogen synthase kinase-3β (GSK-3β; #9315), phospho-GSK-3β (Ser9) (#9322) and histone-H3 (#4499) were from Cell Signaling Technology, Inc. An antibody against α-smooth muscle actin (α-SMA; NBP2-22120) was purchased from Novus
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| Reagents and antibodies
Biologicals. An antibody against peroxisome proliferator-activated receptor gamma (PPAR-γ; sc-7273) was purchased from Santa Cruz
Biotechnology. An antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH; TA-08) was purchased from ZSGB-BIO.
| Cell culture
Primary rat VSMCs were extracted from 8-week-old non-CKD male Wistar rats. Briefly, the rats were killed by sodium pentobarbital, and the thoracic aorta was dissected out quickly. After removing the adventitia and intima, the artery segment was cut into 1-2 mm 2 sections and placed in a cell culture flask with DMEM containing 4.5 g/L glucose supplemented with 20% FBS, 10 mmol/L sodium pyruvate, 100 U/mL penicillin and 100 μg/mL streptomycin (growing medium).
Cells were incubated at 37°C in a humidified atmosphere containing 5% CO 2 . Immunocytochemical examination showed positive staining in all cells for α-smooth muscle actin. Migrated VSMC passages 3-8 were used for in vitro experiments.
Vascular smooth muscle cells were seeded onto a 6-or 12-well dish and incubated with DMEM + 10% FBS (Gibco; Thermo Fisher Scientific, Inc), and 10 mmol/L β-GP (Sigma-Aldrich) was introduced to induce VSMC calcification for 3-12 days. The culture medium was replaced every 3 days. For drug-treated groups, VSMCs were preincubated with different concentrations of Rb1 for 1 hour, followed by β-GP calcification induction together with Rb1. Furthermore, SKL2001, an agonist of the Wnt/β-catenin pathway as reported, 22, 23 was applied to study pathway alteration. VSMCs were pre-treated with 5 μmol/L GW9662 or different doses of SKL2001 (Selleck Chemicals) for 30 minutes, followed by 40 μmol/L Rb1 treatment with or without 10 mmol/L β-GP. Male Wistar rats (160-180 g) were randomly divided into three groups: control, CKD and CKD with ginsenoside Rb1 (CKD + Rb1), n = 5 per group. For CKD and CKD + Rb1 rats, adenine was administered intragastrically at a dose of 250 mg/kg/d for 2 weeks, followed by 250 mg/kg every other day for 4 weeks to establish CKD models based on the previous report. 24 Control rats were given saline intragastrically at an equal volume. For CKD + Rb1 rats, ginsenoside Rb1 was administered intraperitoneally at a dose of 40 mg/kg/d, while an equal volume of saline was administered to CKD rats intraperitoneally. Bodyweights were assessed every 3 days, and the drug dose varied accordingly. After 6 weeks, the animals were killed, and rat serum was collected to determine the blood urea nitrogen (BUN), creatinine (Cr), calcium, phosphorus and alkaline phosphatase (ALP) levels by an autoanalyzer (Chemray 240; Rayto Life and Analytical Sciences Co., Ltd). The abdominal arteries were excised for further analysis.
| Animal experiments
| Alizarin red S staining and von Kossa staining
Vascular smooth muscle cell calcification was induced using 10 mmol/L β-GP for 12 days as described above. 25 After 12 days, VSMCs were washed with PBS three times and fixed in 70% ethanol for 60 minutes at room temperature. After rinsing with PBS, VSMCs were exposed to 1 mg/mL alizarin red S solution (pH 4.2) for another 60 minutes in the dark.
For artery calcification staining, 3 μm paraffin-embedded artery sections were stained with alizarin red S solution for 10 minutes after the standard dewaxing procedure. Von Kossa staining of artery sections was also performed to confirm calcification. Dewaxed sections were exposed to a 5% silver nitrate solution and were placed under an ultraviolet light for 2 hours.
| ALP activity and calcium content detection
The Alkaline Phosphatase Assay Kit (A059-2) and Calcium Assay Kit (C004-2) were from Nanjing Jiancheng Bioengineering Institute.
The ALP activity and calcium content were determined according to the manufacturer's instructions. The results were then normalized by the protein content determined by the BCA Protein Assay Kit (PC0020) from Solarbio. histone-H3 (1:1000 dilution) and GAPDH (1:1000 dilution) overnight. The membranes were then washed with TBS-T, followed by an incubation with a horseradish peroxidase-conjugated secondary antibody (1:8000 dilution) (ZSGB-BIO) for 1.5 hours at room temperature; then, the membranes were developed with chemiluminescence and were stripped and reprobed when necessary.
| Western blot analysis
| Immunohistochemistry (IHC)
Following the standard procedure, paraffin-embedded rat artery sections were rehydrated by dimethylbenzene and gradient ethanol.
Then, 0.05 mol/L sodium citrate buffer (pH 6.0) was introduced for heat-mediated antigen retrieval. Slides were submerged in 3% hydrogen peroxide for 10 minutes to remove endogenous peroxidase.
After a wash step, the slides were blocked with 10% goat serum (ZLI-9021; ZSGB-BIO) for 30 minutes at 37°C, followed by an overnight incubation with primary antibodies against α-SMA (1:500 dilution), calponin 1 (1:200 dilution) and RUNX2 (1:100 dilution) at 4°C in a humid box. After 30 minutes of incubation with the appropriate secondary antibody at 37°C, the slides were reacted with DAB solution (ZSGB-BIO). Haematoxylin was applied to counterstain the nucleus. The tissue sections were visualized under a Nikon Eclipse 80i microscope equipped with a digital camera (DS-Ri1; Nikon) and were analysed with Image-Pro Plus 6.0 software.
| Immunofluorescence (IF) and confocal microscopy
After rehydration, heat antigen retrieval, and 3% H 2 O 2 treatment, the artery sections were permeabilized with 0.3% Triton X-100 (T8200; Solarbio) for 15 minutes. After washing with PBS, the slides were then blocked and probed with the appropriate antibodies as described in the IHC procedure. Antibodies against β-catenin (1:100 dilution) and PPAR-γ (1:100 dilution) were used in this study. After washing, the slides were incubated with a secondary antibody For the VSMC IF procedure, cells were seeded onto coverslips in a 24-well plate and treated as described above. After fixation with immunostaining fixation solution (P0098; Beyotime Biotechnology) for 1 hour at room temperature, VSMCs were blocked, probed with antibodies, stained with DAPI and observed as artery sections.
| Statistical analysis
All experiments were independently repeated at least three times.
Data are expressed as the mean ± SEM. GraphPad Prism 6.0 was used to analyse the data and draw figures. Multiple group data were analysed by one-way ANOVA, followed by Tukey's post hoc test. P < .05 was considered significantly different.
| RE SULTS
| Rb1 reduces calcium deposition in vivo and in vitro
Rat CKD was induced by adenine gavage. As shown in Table 1 , adenine-treated rats developed severe CKD, with significantly higher BUN and creatinine levels (P < .01) than the control rats. Moreover, serum calcium levels in CKD rats did not change, whereas the serum phosphorus (P < .01) and ALP (P < .05) levels were increased. Rb1 administration did not ameliorate CKD rats' renal function but lowered the serum phosphorus levels (P < .05).
To assess vascular medial calcification in adenine-induced CKD rats, alizarin red S staining and von Kossa staining were performed.
As shown in Figure 1A 
| Rb1 inhibits VSMC phenotype switching in vivo and in vitro
Calcification has been demonstrated to be a multifactorial vascular change rather than a simple calcium deposition, and the os- These results suggest that ginsenoside Rb1 inhibits the osteogenic transformation of VSMCs in vivo and in vitro.
| The Wnt/β-catenin pathway is activated in β-GP-induced VSMC calcification
Sufficient studies have shown that the CKD procalcific environment induces Wnt/β-catenin pathway activation, which in turn, promotes the development of VC. [8] [9] [10] 26 Here, we demonstrated that β-GP stimulation for 6 hours promoted the phosphorylation of GSK-3β (Ser9) and β-catenin (Ser675) (P < .01; Figure 3A ). Ser675 phosphorylation 
| Rb1 activates PPAR-γ and down-regulates the Wnt/β-catenin pathway
Based on our existing findings, we next aimed to reveal the intracellular mechanism mediating the VC-protective effect of Rb1. Therefore, we detected the expression of the Wnt/β-catenin pathway and the nuclear receptor PPAR-γ. As presented in Figure 4 , IF showed that the decreased expression of PPAR-γ in CKD rats (vs control) was increased in the CKD + Rb1 group, while compared with that in the CKD group, β-catenin expression was decreased in CKD + Rb1 rats ( Figure 4A Figure 4F ). In brief, these data indicate that Rb1 down-regulates the Wnt/β-catenin pathway and activates PPAR-γ.
| Rb1 ameliorates VC by down-regulating the Wnt/β-catenin pathway
Having obtained evidence of the anticalcification effect of Rb1 and the potential involved pathway, we next explored whether pathway alteration changed the VC-protective effect of Rb1. As presented, 
| Rb1 inhibits the Wnt/β-catenin pathway through the activation of nuclear receptor PPAR-γ
The crosstalking between PPAR-γ and the Wnt signalling pathway has been widely discussed in various diseases. [29] [30] [31] Here, IF double staining and Western blot analyses were performed to illustrate the interaction between PPAR-γ and β-catenin. As shown in the IF results, PPAR-γ expression was increased with Rb1 (40 μmol/L) treatment for 24 hours, while costimulation of 5 μmol/L GW9662, a selective PPAR-γ antagonist, blocked this effect. Consistently, the reduced expression of β-catenin by Rb1 administration was augmented with GW9662 costimulation ( Figure 6A ). Moreover, Western blotting for PPAR-γ and β-catenin further confirmed that PPAR-γ activation mediated the Rb1 inhibition of β-catenin (P < .05; Figures   6B and S1D) . Interestingly, GW9662 treatment alone had little impact on PPAR-γ ( Figure 6A ) and even increased PPAR-γ expression ( Figure 6B) . A possible explanation for this might be that GW9662 acts via inhibiting ligand binding to PPAR-γ, while in the absence of these ligands, the expression of PPAR-γ increased due to feedback.
Taken together, Rb1 inhibits the Wnt/β-catenin pathway by activating the nuclear receptor PPAR-γ.
| D ISCUSS I ON
In the present study, we demonstrated that ginsenoside Rb1 ame- Vascular calcification poses a great threat to human health due to its high morbidity and mortality. 32, 33 Studies have shown that CKD patients are prone to VC even in the early stage (25% in stage 3 and 35% in stage 4), and the prevalence rises rapidly once CKD patients start dialysis (over 50%). 34, 35 Consequently, the increased arterial stiffness inflicts left ventricular hypertrophy (LVH) and augmented pulse pressure, which affects coronary perfusion and escalates stroke risk. Calcium deposition in tunica media is the most prominent histological feature of medial VC. Ginsenosides have been widely used as tonic botanical products in the West. PPD and PPT are two subtypes of ginsenosides in terms of chemical structure. 36 Rb1, a PPD type of ginsenoside, is known for its beneficial properties in the CNS, cardiovascular and endocrine systems. [37] [38] [39] Recently, Rb1 has been reported to protect arterial function in pulmonary hypertension and atherosclerosis models. 16, 17 In addition, Xu et al 18 reported that Rb1 alleviated early CKD progression by modulating oxidative stress and inflammation. However, the effect of Rb1 on CKD-VC has not been elucidated. In this study, we demonstrated that Rb1 reduced calcium deposition as well as ALP activity and calcium concentration in CKD rat arteries. Further, the results in primary rat VSMCs also confirmed the protective role of Rb1 in calcium deposition. All of the above findings strengthen the knowledge of the protective property of ginsenoside Rb1 in vascular diseases.
Sufficient evidence has shown that VC involves a pluriform range of pathobiological processes rather than simple calcium deposition, among which, VSMC switching into osteoblast-like cells plays a critical role. In the present study, we showed that the contractile VSMC markers α-SMA and calponin were reduced in CKD rat aortas and calcified VSMCs compared to those in the control rats, and we showed that Rb1 increased the expression of α-SMA and calponin in a dose-dependent manner. RUNX2, an essential transcription factor in osteoblast differentiation and skeletal morphogenesis, 40 was detected here as an osteogenic marker. We proved that the up-regulated expression of RUNX2 was suppressed by Rb1 both in vivo and in vitro, indicating that Rb1 inhibited VSMC phenotype switching of VC. Interestingly, it was demonstrated that ginsenosides promote osteogenic differentiation. [41] [42] [43] [44] Ginsenoside Rg1 promotes rat bone marrow mesenchymal stem cell (rBMSC) osteogenic differentiation by activating the GR/BMP-2 signalling pathway. 41 Moreover, ginsenosides Rg3, Rd and Rh2(S) were reported to induce the differentiation and mineralization of MC3T3-E1 cells. [42] [43] [44] Nevertheless, none of the studies above investigated the effect of Rb1 on VSMC phenotype switching or the role of the PPAR-γ/β-catenin pathway in VC. Interacting with the T cell factor/lymphoid enhancer factor (TCF/ LEF) family, β-catenin regulates the transcription of downstream genes, thereby governing cellular fate determination processes, such as osteogenic differentiation of MSCs. 4 Growing evidence has shown that the Wnt/β-catenin pathway plays a key role in VC. [8] [9] [10] It has been reported that the Wnt/β-catenin pathway mediates the induction of CKD-VC by bone morphogenetic protein-2 (BMP2). 9 High phosphate was reported to activate WNT/β-catenin signalling, which promoted VC via directly modulating Runx2 gene expression. 7 Moreover, several studies have demonstrated that the inhibition of the WNT/β-catenin pathway reduces VC. 10, 45 In this study, the activated Wnt/β-catenin pathway and enhanced nuclear translocation of β-catenin were observed in β-GP-induced VSMC calcification, which is in accordance with the study by Cai et al. 7 PPAR-γ has been reported to regulate glucolipid metabolism and to determine the differentiation of various cell types. 46, 47 Recently, studies have reported that PPAR-γ is involved in vascular inflammation and atherosclerosis. 48, 49 More importantly, activation of PPAR-γ has been demonstrated to maintain the VSMC phenotype, and the down-regulation of PPAR-γ contributes to CKD-associated VC. 8, 50 Belonging to the steroidal saponin family, ginsenosides share a similar structure with steroid hormones, which can traverse the membrane and disrupt the genome. 36 Furthermore, it has been reported that PPT may act as a PPAR-γ ligand that is involved in the PPAR-γmediated transactivation of target genes. 51 In the present study, we found that PPAR-γ was significantly decreased in CKD rat aortas, The interplay between PPAR-γ and the Wnt signalling pathway has been extensively discussed. For example, the PPAR-γ and Wnt pathways orchestrate the adipogenesis and osteogenesis of MSCs. 12 Jiajian Liu, et al reported that the functional interaction between β-catenin and PPAR-γ involved the TCF/LEF-binding domain of β-catenin and a catenin-binding domain (CBD) within PPAR-γ. 55 In this study, we substantiate the interaction between PPAR-γ and β-catenin by GW9662 intervention, indicating that Rb1 inhibited the Wnt/β-catenin pathway through the upstream activation of PPAR-γ.
Nevertheless, insufficiency of this study remains in that, despite being a generally accepted model of CKD, adenine-induced CKD rats suffered faster weight loss and less extensive VC than clinical CKD patients due to the gavage modelling time being relatively intense and limited, which requires future studies for further exploration.
Overall, as illustrated in the schematic diagram ( Figure 6C ), this study first demonstrated that ginsenoside Rb1 ameliorates CKD-associated VC by inhibiting the Wnt/β-catenin pathway by activating PPAR-γ. These promising findings provide novel insights into the potential conversion of natural products into clinical therapeutics for VC. 
ACK N OWLED G EM ENTS
CO N FLI C T O F I NTE R E S T
None. 
AUTH O R CO NTR I B UTI
O RCI D
Xiaoping Ji https://orcid.org/0000-0002-1935-2239
Huixia Lu https://orcid.org/0000-0003-0131-5808
